Who We Are
HepaPredict AB is a contract research organization (CRO) specializing in drug metabolism, toxicity, and drug development for liver disease. We offer in-house evaluations of drug metabolism, pharmacokinetic properties and safety, as well as drug target validations based on our well established long-term stable physiological 3D spheroid culture platform.
We are the only company that provides this 3D spheroid platform for predictive in vivo metabolism and toxicity. Integrated with preclinical solutions and scientific consultancy for drug discovery and optimized lead selection we aim for:
Improved preclinical selection of drug candidates for clinical development.
Shortened times and reduced costs of drug development times.
Development of novel medications against hepatic diseases.
HepaPredict uses the most extensively characterized 3D spheroid system available, offering unmatched accuracy in predicting hepatotoxicity and evaluating toxicity mechanisms. We offer:
Tailored experimental designs and readouts.
Rapid turnaround of results and reports.
Extensive customer support from project initiation to closure.
Integrative analysis of results by experienced toxicologists.
Consulting about future steps and recommendations for follow-up studies.
HepaPredict AB was founded in 2016 as a private spin-off from Karolinska Institutet, Stockholm, Sweden.
Our ambition is to commission our scientific experience and expertise to deliver highest-quality science with the goal to support and optimize drug development efficacy and safety.
Our Team
Prof. Volker M. Lauschke, PhD, MBA - Co-founder and CEO
Volker obtained his PhD from the EMBL and the Combined Faculty of Natural Sciences and Mathematics of the University of Heidelberg, Germany for the development of a novel primary cell culture system and his work on tissue patterning based on phase-encoding using molecular oscillators. In 2014, he moved to Karolinska Institutet as a MarieCurie fellow to work on the development of physiological hepatic model systems. He is Assistant Professor for Liver function and regeneration with emphasis on drug development since Jan. 2017. His research is focused on hepatic toxicity and disease models, hepatocyte differentiation plasticity in health and disease as well as the genetic basis of drug response.
In addition, Volker obtained a BBA degree from the University of Hagen, Germany, and has successfully completed academic courses Law.
Prof. Magnus Ingelman-Sundberg, PhD - Co-founder and Chairman of the Board
Magnus Ingelman-Sundberg: BSc in Medicine, PhD and Docent in Physiological Chemistry, Professor of Molecular Toxicology at Karolinska Institutet, Stockholm Sweden. Member of several Editorial Advisory Boards and recipient of multiple awards in the field of drug metabolism and toxicity. More than 440 original papers, 26 000 citations and an h-factor of 85. Member of The Nobel Assembly at Karolinska Institutet since 2008. Recently categorized by Thomson Reuters as one of the World’s Most Influential Scientific Minds.
Sabine U. Vorrink, PhD - Chief Operating Officer (COO)
Sabine obtained her PhD in Human Toxicology from the University of Iowa, Iowa, USA in 2014. She joined the lab of Magnus Ingelman-Sundberg at Karolinska Institutet as a postdoctoral fellow in 2015 where she extensively characterized the 3D spheroid model developed at the time. In 2017 Sabine joined HepaPredict to establish the lab and initial operations. Ever since Sabine has been overseeing the daily operations and strategic initiatives to ensure organizational efficiency and growth.
Bo Qwarnstrom, MBA - Member of the Board
Bo Qwarnstrom holds a BSc in Economics from Uppsala University and a MBA from the Ivey School of Business, London, Canada. More than 40 years career in medical business. Co-founder of Guidor AB (guidor.com), now a subsidiary of Japanese Sunstar Group. Co-founder of OssDsign AB (ossdsign.com), today on the Stockholm Nasdaq stock exchange. Owner and principal consultant of Guiden SA, Nyon, Switzerland. Guiden is an international medical consulting business with a portfolio of more than 200 assignments concluded in life science.